 |
| About ImQuest | Meet the Management |
| |
| Board of Directors |
 |
Daniel R. Caffoe, Chairman of the Board |
|
Daniel A. Biehl, Director |
|
Robert W. Buckheit, Jr., Ph.D., Director
|
 |
Dan Williams, JD, LLM, Vice President of Tax and Chief Financial Officer |
| |
| Scientific Advisory Board |
|
Richard J. Whitley, M.D. |
|
Robert T. Schooley, M.D. |
|
Albert F. LoBuglio, M.D. |
|
David Ho, M.D. |
|
Dan Von Hoff, M.D. |
|
Edward Sauseville, M.D. |
 |
| |
| |
 |
| Richard J. Whitley, M.D. |
| Dr. Whitley is Professor of Pediatrics, Microbiology and Medicine at the University of Alabama at Birmingham; Loeb Scholar in Pediatrics; Director, Division of Pediatric Infectious Diseases; Vice-Chair, Department of Pediatrics; Senior Scientist, Department of Gene Therapy; Senior Scientist, Cancer Research and Training Center; Associate Director for Clinical Studies, Center for AIDS Research; Director, Center for Biodefense and Emerging Infections, The University of Alabama at Birmingham. Dr. Whitley is responsible for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group whose role is to perform clinical trials of antiviral therapies directed against medically important viral diseases of children and adults. Dr. Whitley's other research interest is in the translation of molecular biology to clinical application, particularly in the development of human monoclonal antibodies for therapy and engineering of herpes simplex virus for gene therapy. He is a past President of the International Society of Antiviral Research. He has been elected to the Infectious Diseases Society of America, Fellow, American Society of Microbiology, American Society of Clinical Investigation and Association of American Physicians. |
|
|
| Robert T. Schooley, M.D. |
| Dr. Robert Schooley is Professor of Medicine and Head of the Division of Infectious Diseases at the University of California, San Diego. He is a graduate of Washington and Lee University and of the Johns Hopkins University School of Medicine. After medical house staff training at the Johns Hopkins Hospital and postdoctoral fellowships in Infectious Diseases at the National Institute of Allergy and Infectious Diseases and the Massachusetts General Hospital, he joined the faculty of Harvard Medical School in 1981. He was recruited from Harvard to the University of Colorado School of Medicine in 1990 where he served as Tim Gill Professor and Head of the Division of Infectious Diseases. He assumed his current position in 2006. He led the NIAID's AIDS Clinical Trials Group (ACTG) from 1995 - 2002. His research interests are in the areas of viral pathogenesis and therapy with a particular emphasis on retroviruses, herpes viruses and hepatitis C virus. He has contributed to the development of most of the currently available antiretroviral agents. He has authored over 200 publications |
| |
|
| Albert F. LoBuglio, M.D. |
Albert F. LoBuglio, M.D., a medical oncologist, has been the Director of the Comprehensive Cancer Center at the University of Alabama at Birmingham since 1983. He graduated from Canisius College and Georgetown University School of Medicine. He received his Internal Medicine training at the University of Pittsburgh and subspecialty (Hematology/Oncology) research and training at Harvard (Thorndike Memorial Laboratories). Dr. LoBuglio has held leadership positions in cancer care and research at Ohio State University and the University of Michigan. His expertise has been sought on numerous National Institutes of Health Study Sections, two terms as a member of the Board of Scientific Councilors at the National Cancer Institute and as a scientific advisory board member for multiple companies involved in biologic therapy.
Dr. LoBuglio has a thirty-year track record of competitively funded human tumor immunology research with a major emphasis on early clinical trials of monoclonal antibodies and vaccines over the past fifteen years. He has extensive experience in the design of early clinical trials with biologic reagents emphasizing translational research with strong laboratory preclinical and early clinical trial observations. His group has considerable expertise in working with genetically engineered targeting reagents, including conjugates with radioisotopes, toxins, drugs, and other antitumor reagents. Although he provides leadership for a large comprehensive cancer center, he continues to see patients and design early clinical trials. |
| |
|
| David Ho, M.D. |
| David D. Ho, M.D. is the founding Scientific Director and Chief Executive Officer of the Aaron Diamond AIDS Research Center, a world-renowned biomedical research institute. He is also the Irene Diamond Professor at The Rockefeller University. Dr. Ho received his degrees from California Institute of Technology (1974) and Harvard Medical School (1978). Subsequently, he did his clinical training in internal medicine and infectious diseases at Cedars-Sinai Medical Center/UCLA School of Medicine (1978-1982) and Massachusetts General Hospital/Harvard Medical School (1982-1985), respectively. Dr. David Ho has been at the forefront of AIDS research for 26 years, publishing over 350 papers. His elegant studies, beginning in 1994, unveiled the dynamic nature of HIV replication in vivo and revolutionized our basic understanding of this horrific disease (Nature 1995; Science 1996). This knowledge led Dr. Ho to champion combination antiretroviral therapy (N. Engl. J. Med. 1995; Science 1996) that resulted in unprecedented control of HIV in patients (Nature 1997). AIDS mortality in richer nations has declined 6-fold since 1996, and a massive international effort is now underway to bring such life-saving treatment to millions in the developing world. Dr. Ho has been the major driving force behind this major medical breakthrough in what is arguably the worst plague in human history. Dr. Ho's research team is now devoting considerable efforts to develop vaccines to halt the spread of the AIDS epidemic. Furthermore, he is now heading up a consortium of Chinese and American organizations to help address the crisis of HIV/AIDS in China. Dr. Ho has received numerous honors and awards for his scientific accomplishments. He is the recipient of nine honorary doctorates (including from Swarthmore, Tufts, Columbia, Tulane, University of Natal, and Tsinghua University). He has been chosen as the commencement speaker at Caltech, MIT, and Harvard School of Public Health. Additional accolades include the Ernst Jung Prize in Medicine, Mayor's Award for Excellence in Science & Technology, the Squibb Award, and the Hoechst Marion Roussel Award. Dr. Ho has been elected as a member of the American Academy of Arts and Sciences, Academia Sinica (Republic of China), Chinese Academy of Engineering, and the Institute of Medicine, National Academy of Science in the United States. He was recently inducted into the California Hall of Fame. Dr. Ho is also an honorary professor at Peking Union Medical College, Chinese Academy of Medical Sciences, Chinese Academy of Sciences, University of Hong Kong, Wuhan University, and Fudan University. He was a member of the Board of Overseers of Harvard University and the Board of Trustees of the California Institute of Technology. He is a board member of the Massachusetts Institute of Technology Corporation. Dr. Ho was named Time Magazine's Man of the Year in 1996, and was the recipient of a Presidential Medal in 2001. |
| |
|
| Dan Von Hoff, M.D. |
Currently, Dr. Von Hoff is Senior Investigator and Head of Translational Research at the Translational Genomics Research Institute's (TGen) Translational Drug Development Division. He also serves as Head, Pancreatic Cancer Research Program in Phoenix, Arizona, and is Chief Scientific Officer for US Oncology. Dr. Von Hoff's major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the early development of drugs that are now routinely used to treat cancer, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, CPT-11, and others. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies.
A prolific scientific writer, Dr. Von Hoff has published more than 529 papers, 129 book chapters, and more than 892 abstracts. His laboratory interests and contributions have been in the area of in vitro drug sensitivity testing to individualize treatment for the patient. He and his laboratory are now concentrating on discovery of new targets in pancreatic cancer.
Dr. Von Hoff was appointed to President Bush's National Cancer Advisory Board in June 2004 - March 2010. Dr. Von Hoff is the past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX™ Oncology, Inc. (recently acquired by Genzyme). He is founder and the Editor Emeritus of Investigational New Drugs - The Journal of New Anticancer Agents; and, Editor-in-Chief of Molecular Cancer Therapeutics. He is also proud to have been a mentor and teacher for many medical students, medical oncology fellows, graduate students, and post-doctoral fellows. |
| |
|
| Edward Sauseville, M.D. |
| Edward A. Sausville, M.D., Ph.D. is the Associate Director for Clinical Research of the University of Maryland Marlene and Stewart Greenebaum Cancer Center. He is also Professor of Medicine, Adjunct Professor of Pharmacology and Experimental Therapeutics in the University of Maryland School of Medicine, and Affiliate Professor in the University of Maryland School of Pharmacy. He graduated from Manhattan College with a degree in Biochemistry in 1973, and received his Ph.D. in Pharmacology in 1978 and M.D. in 1979 from the Albert Einstein College of Medicine of Yeshiva University in New York City. Following medical house-staff training at the Brigham and Women's Hospital in Boston, he was a Medical Staff Fellow at the National Cancer Institute (NCI), National Institutes of Health in Bethesda, MD. He was a Senior Investigator at NCI until 1988, when he went to Georgetown University as Associate Professor of Medicine. He returned to the NCI in 1990, and for ten years through 2004 was Associate Director of the Division of Cancer Treatment and Diagnosis for the Developmental Therapeutics Program. Dr. Sausville is board certified in Internal Medicine and Medical Oncology. Dr. Sausville's areas of expertise include cancer biology, and cancer drug development and therapy. |
| |
|
| Daniel R. Caffoe, Chairman of the Board |
| Mr. Caffoe is a founding member of the family of ImQuest Companies which began in 2001 and he became the interim CEO and Chairman of ImQuest Life Sciences early in 2008. He has been a very important part of the company’s reorganization that began late in 2007 and has implemented a new development plan to recruit new management that will allow ImQuest to raise the additional funds needed to move the company’s products to human clinical trials. From 1979 until 1993 Mr. Caffoe owned and operated his own golf facilities and then in 1994 he became a Life Member of the Professional Golfers Association of America. Mr. Caffoe is currently a licensed Insurance and Mortgage Broker in the State of Indiana. He has also been involved in the real estate industry as an investor and developer and has owned and operated a number of different businesses during his lifetime. |
| |
|
| Daniel A. Biehl, Director |
| Daniel Biehl, MD, a northwestern Michigan native, attended Michigan Tech University and Wayne State University School of Medicine. After completing a residency in General Pediatrics at Michigan State University, he concluded his formal training with a fellowship in Neonatal-Perinatal Medicine at the University of Louisville. During his fellowship, Dr. Biehl’s research was in clinical applications of ECMO. Dr. Biehl moved to Fort Wayne, Indiana, in 1998, after serving in the Air Force where he was the director of ECMO for Wilford Hall for 3 years. Dr. Biehl is the Medical Director of the Neonatal Intensive Care Units at both Lutheran Hospital and St. Joseph Hospital in Fort Wayne, Indiana and he holds board seats at both Monroe Hospital in Bloomington, Indiana and the Children’s Hope House of Fort Wayne. Outside of medicine, his interests include training for a number of different types of marathons in which he participates. He’s striving to compete in at least one marathon in all 50 states and to date has competed in 35 different states. |
| |
|
| Robert W. Buckheit, Jr., Ph.D., Director |
Dr. Buckheit is President and Chief Scientific Officer of ImQuest BioSciences, Inc., a contract research services provider dedicated to the rapid development of anti-infective and anti-cancer therapeutics.
Since 1989, Dr. Buckheit has been intimately involved in the preclinical development of anti-infective agents with a focus on agents for use against HIV. During this period of time Dr. Buckheit has developed and managed infectious disease research programs for commercial, academic and government clients at both Southern Research Institute and TherImmune Research Corporation/Gene Logic Inc. During these past 15 years, Dr. Buckheit has managed a variety of multi-million dollar and technically complex federal contracts, hundreds of programs with virtual and small biotechnology companies, research programs with pharmaceutical industry companies and collaborative programs with academic investigators. Dr. Buckheit's experience with anti-infective evaluations includes the evaluation of well over 250,000 anti-infective molecules and has resulted in a wide variety of publications in the peer reviewed literature.
Dr. Buckheit participated in several National Cooperative Drug Discovery Group Programs, in Drug and Vaccine Evaluation programs, Topical Microbicide Development Programs and programs involving the development of vaccines to potential biodefense agents. In addition to HIV, Dr. Buckheit directed programs involving herpes viruses, hepatitis B and hepatitis C, respiratory and enteric viruses and agents of potential bioterrorism.
Dr. Buckheit oversees the entire Scientific team at ImQuest's Laboratory located in Frederick, Maryland. |
| |
|
|
